Arpida neuer Tip - neue Superchance - 500 Beiträge pro Seite

[stockbaby]

Interessanter Tip aus dem Börse-online Heft: Arpida
Phase III Blockbuster-Produkt gegen Krankenhauskeime, niedrige Marktkapitalisierung von 150 Millionen Teuros, Übernahmekandidat oder Auslizenzierung und noch fast total unbekannt.
Hier sind alle Chancen gegeben, habe mich mal mit ner kleinen Position eingedeckt, vielleicht wirds ja was.
Was haltet Ihr davon???

Übrigens für Mologen werben sie mit ner 1000% chance.

[Fruehrentner]

Interessanter Wert! (aus der Schweiz: www.arpida.ch).

Mal auf die watchlist nehmen.



Hier eine Meldung von vorgestern:

Arpida presents positive trial oral iclaprim data

14/02/2006- Arpida has announced it has successfully completed a Phase I clinical trial with oral iclaprim in a capsule formulation. This broad-spectrum antibiotic targets infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Oral iclaprim could offer significant benefits as a switch from intravenous to oral administration, enabling patients to be discharged from hospitals earlier by allowing them to continue and complete their treatment at home.
This switch potentially lowers healthcare costs while at the same time reducing the probability of the patient contracting new infections.

The primary objective of this study was to assess the bioavailability of iclaprim from an oral capsule formulation as compared to the intravenous formulation.

In this Phase I trial, eight healthy volunteers received one dose of oral iclaprim and one dose of intravenous iclaprim for comparative purposes.

The results show an oral bioavailability of iclaprim from the capsule of around 40 per cent and confirm that oral administration of iclaprim can easily achieve blood levels comparable with those of therapeutic doses of intravenous iclaprim.

These results confirm those of a study investigating the solution formulation of oral iclaprim.

"These studies indicate that oral administration of iclaprim can achieve an exposure comparable to the dose that is used in the on-going Phase III trial with intravenous iclaprim," said Dr Khalid Islam, president and CEO of Arpida.

"We strongly believe that the availability of an oral formulation will be one of the key differentiating features of iclaprim over virtually all of the antibiotics for the treatment of bacterial infections including MRSA," he added.

Arpida has now successfully completed three Phase I trials with oral formulations of iclaprim: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled iclaprim, a bioavailability study with a solution and one with a capsule formulation.

Additional Phase I trials are planned during the year and are expected to provide the foundation for later-stage clinical trials.

Meanwhile, the intravenous formulation of iclaprim is currently in Phase III trials for the treatment of complicated skin and skin structure infections (cSSSI).

Such is the extent of the situation, the US Food and Drug Administration (FDA) has granted fast track status to intravenous iclaprim for the treatment of cSSSI.

MRSA is a type of bacteria that is resistant to almost all antibiotics. These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin and amoxicillin. S. aureus infections, including MRSA, occur most frequently among persons in hospitals and healthcare facilities (such as nursing homes and dialysis centres) who have weakened immune systems.

It has been estimated that antibiotic resistance costs US society between $4 billion and $5 billion (€3.4 billion - €4.2 billion) annually.

According to the CDC, antibiotic resistance has become so widespread that many significant bacterial infections in the world are becoming resistant to commonly used antibiotics.


http://www.drugresearcher.com/news/ng.asp?n=65819-arpida-mrs…




Hier noch eine etwas ältere Empfehlung:


29.11.2005 11:07:05 (GLOBAL BIOTECH INV.)

Arpida ein klarer Kauf

Für die Experten des Börsenbriefs "Global Biotech Investing" ist die Arpida-Aktie (ISIN CH0021218067/ WKN A0EAKH) ein klarer Kauf.

Die Gesellschaft konzentriere sich auf die Entwicklung neuer Antibiotika, da durch das Auftreten von Resistenzen der Bedarf dieser Medikamente ungebrochen sei. Das Marktvolumen betrage bereits heute rund 26 Mrd. US-Dollar. Arpida habe mit dem Breitbandantibiotika Iclaprim aktuell bereits ein vielversprechendes Präparat in der Phase III der klinischen Studien, welches gegen eine Vielzahl von Bakterienstämmen wirke. Das Medikament könnte schon 2008 für den Vertrieb zugelassen werden.

Per 2009 rechne die Researchabteilung des Bankhauses Vontobel mit dem Erreichen der Gewinnschwelle und habe Ende Oktober die Coverage mit einem "outperform"-Rating und einem Fair-Value des Titels von 24 CHF aufgenommen. Sowohl die Analysten von Lombard Odier Darier Hentsch wie auch die Kollegen der Deutschen Bank hätten das Papier einige Wochen zuvor mit einem klaren "buy"-Rating eingestuft.

Nach Ansicht der Experten des Börsenbriefs "Global Biotech Investing" bleibt die Arpida-Aktie ein klarer Kauf.
Quelle: GLOBAL BIOTECH INV.